KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng-Ta Yang, Takako Inoue, Makoto Nishio, Yasushi Goto, Tomohide Tamura, Nobuyuki Yamamoto, Chong-Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa

Cancer Sci 117(4) 1124-1135

PMID41611341
PMCIDPMC13045390
DOI10.1111/cas.70330
发表日期2026-01-29
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the Phase III TASUKI-52 trial, nivolumab with carboplatin, paclitaxel (CP), plus bevacizumab significantly prolonged progression-free survival (PFS), and resulted in longer overall survival (OS) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). This final analysis evaluated 4-year treatment outcomes in terms of OS, PFS and duration of response (DOR) by investigator assessment and safety, as well as the background characteristics and treatment courses associated with 4-year survivors. Patients were randomized 1:1 to receive nivolumab (n = 275) or placebo (n = 275) in addition to CP plus bevacizumab. With a minimum follow-up of 53.1 months, nivolumab with CP plus bevacizumab continued to show improvement in OS (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.58-0.88) and PFS (HR: 0.61; 95% CI: 0.50-0.74) compared to placebo with CP plus bevacizumab. The 4-year OS rate was 34.7% in the nivolumab arm versus 22.1% in the placebo arm, and the 4-year PFS rate was 13.7% in the nivolumab arm versus 3.3% in the placebo arm. Among 4-year survivors, the median DOR was numerically longer in the nivolumab arm than in the placebo arm (34.7 vs. 13.5 months). No new safety signals were observed. Four-year survival in the nivolumab arm was associated with the absence of bone metastases and age < 65, but not with PD-L1 status and tumor size. In conclusion, treatment with nivolumab demonstrated long-term survival benefit and durable response, which supports nivolumab with CP plus bevacizumab as a first-line treatment option for advanced nonsquamous NSCLC. Trial Registration: ClinicalTrials.gov identifier: NCT03117049.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 1

FIGURE 1 Overall survival (OS). (a) Kaplan–Meier for OS of the intention‐to‐treat (ITT) population in the nivolumab and placebo arms. a Stratified hazard ratio (HR). (b) Forest plot of subgroup analysis for OS. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PD‐L1, programmed death‐ligand 1; PS, performance status.

A

Overall survival (OS)

FIGURE 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

KM endpoint

FIGURE 1 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact
查看结果
KM Figure1 个面板

FIGURE 2

FIGURE 2 Progression‐free survival (PFS) by investigator assessment. Kaplan–Meier for PFS of the intention‐to‐treat (ITT) population in the nivolumab and placebo arms. a Stratified hazard ratio (HR). CI, confidence interval.

PFS_Kaplan-Meier_curve

PFS

FIGURE 2 · Panel PFS_Kaplan-Meier_curve

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS_Kaplan-Meier_curve 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果